Rogelio Braceras, MD: Improving Costs, Comorbidities in T2D

June 24, 2018 7:17 pm

The Boehringer Ingelheim representative discusses how the future of empagliflozin research should shape out.

Category: News
About The Author
-
Previous

Zanetti et al; Birthweight, T2D, and Cardiovascular Disease
Next

Reversing T2D with a keto diet — Diet Doctor Podcast with Dr. Sarah Hallberg

Related Videos

Introduction-to-SGLT2-Inhibition

Introduction to SGLT2 Inhibition

Hua-Medicine-A-Global-Effort-to-Stop-Diabetes

Insulin Treatment Is Associated with Increased Mortality in Patients with COVID-19 and Type 2 Diabetes

Hua-Medicine-A-Global-Effort-to-Stop-Diabetes

Hua Medicine – A Global Effort to Stop Diabetes

Unleashing-the-Truth-How-to-Put-T2D-Patients-Hearts-First

Unleashing the Truth: How to Put T2D Patients’ Hearts First

2038018

The Role of Nutrition in the Prevention and Intervention of Type 2 Diabetes

Type-2-Diabetes-Dr-Hull-The-Focus-of-Treatment-in-T2D

Type 2 Diabetes: Dr Hull – The Focus of Treatment in T2D